Fact Sheet

The U.S. Market for Biosimilars and Biologics Medicines

Since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) in 2010, biosimilars have been viewed as an important way to bolster competition and increase options for patients. It's clear it is achieving its policy goals and that the benefits of the BPCIA on innovation and competition are being realized. Here are three things you should know about the biosimilar market.